Cureill Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 0.75%
(FY 2023)
- Profit 18.76%
(FY 2023)
- Ebitda 15.95%
(FY 2023)
- Net Worth 19.43%
(FY 2023)
- Total Assets -0.60%
(FY 2023)
About Cureill Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jigneshkumar Patel, Hareshkumar Patel, Hinal Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100GJ2014PTC080448
- Company No.
080448
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cureill Pharma Private Limited offer?
Cureill Pharma Private Limited offers a wide range of products and services, including Third Party Manufacturing Consultancy, Nutraceutical Third Party Manufacturing, Manufacturing & Assembling Services, Heat Treating Services.
Who are the key members and board of directors at Cureill Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikashkumar Patel  | Director | 09-Mar-2021 | Current |
| Jigneshkumar Patel | Director | 12-Aug-2014 | Current |
| Hareshkumar Patel | Director | 12-Aug-2014 | Current |
| Hinal Patel | Director | 14-Jul-2017 | Current |
Financial Performance of Cureill Pharma.
Cureill Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.75% increase. The company also saw a substantial improvement in profitability, with a 18.76% increase in profit. The company's net worth Soared by an impressive increase of 19.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cureill Pharma?
In 2023, Cureill Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cureill Pharma?
Cureill Pharma has a workforce of 48 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cureill Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cureill Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
